Disc Medicine announces $62.5M registered direct offering

Disc Medicine announced it has entered into a securities purchase agreement with certain investors resulting in an aggregate $62.5M in gross proceeds through a registered direct offering. The financing was led by Bain Capital Life Sciences, who contributed $50M, with participation from existing investors, Access Biotechnology and OrbiMed. The financing includes 1,488,166 shares of the company’s common stock at a price of $23.00 per share and pre-funded warrants to purchase up to an aggregate of 1,229,224 shares of common stock, at a purchase price of $22.9999, which represents the per share offering price for the common stock less the $0.0001 exercise price for each pre-funded warrant. The offering is expected to close on or about February 15, 2023, subject to customary closing conditions.